Navigation Links
Adding Radiation Therapy For Treatment of Advanced Prostate Cancer May Offer Benefit

py group (median metastasis-free estimate, 14.7 years), a difference that was not statistically significant. There were no significant between-group differences for overall survival (71 deaths in the radiotherapy group vs. 83 deaths in the observation group).

The researchers did find that patients in the adjuvant radiotherapy group had a 57 percent lower risk of PSA relapse, and a 38 percent reduced risk of disease recurrence, compared to patients in the observation group.

Adverse effects were more common with radiotherapy vs. observation (23.8 percent vs. 11.9 percent), including rectal complications and urinary incontinence.

"The results of this study provide guidance for clinicians and patients in weighing options for adjuvant radiotherapy for pathologically advanced disease. Arguments in favor of radiation include the approximately 50 percent reduction in risk of PSA relapse or disease recurrence, and perhaps the nonsignificant reduction in risk of metastasis-free survival, the primary study end point," the authors write. "Arguments against adjuvant radiotherapy must include that the study had negative findings, ie., a significant reduction in metastatic disease was not demonstrated. Despite prolonged follow-up of these patients, the rate of metastatic disease was significantly less than anticipated."

Source-Newswise
'"/>




Page: 1 2

Related medicine news :

1. Adding contrast improves ultrasounds ability to detect prostate cancer
2. Adding Fish to Diet May Reduce Risk of Alzheimers
3. Adding An Additional Drug May Help Patients With Glaucoma
4. Adding Credit To The Health Care Industry In India
5. Adding Sorghum Compounds To Dietary Supplements May Help Lower Cholesterol
6. Adding more fiber in the diet can offset hemorrhoids.
7. Trans Fats Adding Inches to the Waistline
8. Replacing Old Mattress, Adding Ventilation Reduces Mites
9. Radiation before surgery cuts cancer recurrence
10. UV Radiation induces Melanoma
11. Radiation reduces cancer recurrence
Post Your Comments:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6JumpStart Invests in Checkpoint Surgical 6118 1JumpStart Invests in Checkpoint Surgical 6118 2JumpStart Invests in Checkpoint Surgical 6118 3Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2
Other Medicine Technology:Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9Video: Actress and New Mom Keri Russell Joins PKIDs to Launch 'Silence the Sounds of Pertussis' Campaign 2Video: Actress and New Mom Keri Russell Joins PKIDs to Launch 'Silence the Sounds of Pertussis' Campaign 3